Lionbridge Technologies, Inc., the translation and digital communications company, announced updates to its Clinical Labeling translation solution, an end-to-end offering that helps global life sciences organizations translate labeling content for clinical studies while remaining compliant with global regulatory requirements.
The features of the Clinical Labeling solution include an updated, fully customizable workflow for label text creation, translation and validation across more than 100 markets and languages. In addition, Lionbridge Life Sciences has integrated its labeling translation solution with suppliers of clinical labeling design, production, and management services, allowing integration of translation processes within clients' existing labeling management platforms.
"As a global leader in clinical supply chain solutions, we needed a partner that could deliver accurate clinical labels while integrating regulatory compliance, packaging capabilities and country validation," said Jamie Pieron, Manager of Client Services Operations, Clintrak Clinical Labeling Services. "By leveraging Lionbridge's expansive global regulatory network and expertise, we can continue to provide our clients with a clinical labeling model that improves efficiency and reduces overall risk."
Lionbridge's technology platform, combined with Lionbridge's network of qualified translators and regulatory experts enables pharmaceutical and biotechnology organizations to reduce the overall label cycle times and simplify global label creation. Key benefits of the updated Lionbridge Clinical Labeling solution include:
To learn more, visit http://lifesciences.lionbridge.com/what-we-do/services-function/regulatory/.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.